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Cambridge, United KingdomABSTRACT The 5-HT3 receptor is a member of the Cys-loop family of transmitter receptors. It can function as a homopentamer
(5-HT3A-only subunits) or as a heteropentamer. The 5-HT3AB receptor is the best characterized heteropentamer. This receptor
differs from a homopentamer in its kinetics, voltage dependence, and single-channel conductance, but its pharmacology is
similar. To understand the contribution of the 5-HT3B subunit to the binding site, we created homology models of 5-HT3AB
receptors and docked 5-HT and granisetron into AB, BA, and BB interfaces. To test whether ligands bind in any or all of these
interfaces, we mutated amino acids that are important for agonist and antagonist binding in the 5-HT3A subunit to their corre-
sponding residues in the 5-HT3B subunit and vice versa. Changes in [3H]granisetron binding afﬁnity (Kd) and 5-HT EC50
were determined using receptors expressed in HEK-293 cells and Xenopus oocytes, respectively. For all A-to-B mutant recep-
tors, except T181N, antagonist binding was altered or eliminated. Functional studies revealed that either the receptors were
nonfunctional or the EC50 values were increased. In B-to-A mutant receptors there were no changes in Kd, although EC50 values
and Hill slopes, except for N170T mutant receptors, were similar to those for 5-HT3A receptors. Thus, the experimental data do
not support a contribution of the 5-HT3B subunit to the binding pocket, and we conclude that both 5-HT and granisetron bind to an
AA binding site in the heteromeric 5-HT3AB receptor.INTRODUCTIONThe 5-HT3 receptors are members of the Cys-loop receptor
superfamily of ligand-gated ion channels, which includes
the nicotinic acetylcholine (nACh), GABAA, and glycine
receptors (1). These receptors are membrane proteins and
function as a pentameric arrangement of subunits. Five
5-HT3 receptor subunits (5-HT3A–5-HT3E; the nomencla-
ture employed in this work adopts the recent recommenda-
tions of the NC-IUPHAR (2)) have been identified to date,
although only homomeric 5-HT3A and heteromeric
5-HT3AB receptors have been extensively characterized
(3,4). The 5-HT3B subunit shares 45% sequence identity
with the 5-HT3A subunit, but, in contrast to the 5-HT3A
subunit, fails to produce homomeric functional receptors
(5). However, 5-HT3B subunits coexpress with 5-HT3A
subunits to yield functional heteromeric complexes with
a proposed subunit stoichiometry of 2A:3B, and a proposed
subunit arrangement of B-B-A-B-A (6).
Studies of 5-HT3AB receptors in heterologous systems
have revealed that the 5-HT3B subunit alters several
biophysical properties of the 5-HT3 receptor, including the
EC50 for 5-HT, receptor desensitization kinetics, current-
voltage relationship, Hill slope, and permeability to Ca2þ
(7,8). In addition, heteropentameric 5-HT3AB receptors
display a large single-channel conductance (16 pS), which
contrasts with the almost nondetectable single-channel
conductance of homopentameric 5-HT3A receptors (0.4 pS)
(3,9). Further studies led to the discovery of a cytoplasmicSubmitted June 3, 2009, and accepted for publication December 2, 2009.
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0006-3495/10/04/1494/9 $2.00region (HA-stretch) that determines the single-channel con-
ductance in 5-HT3 receptors. Replacement of three Arg resi-
dues unique to the HA-stretch of the 5-HT3A subunit by
their 5-HT3B subunit counterparts increased single-channel
conductance 28-fold (9–12).
The agonist-binding domain of 5-HT3 receptors can
reasonably be extrapolated from crystal structures of acetyl-
choline-binding proteins (AChBPs) (13), and a range of
homology models for the homopentameric 5-HT3A receptor
have been constructed (14–17). Amino acid residues from
six discontinuous regions of the extracellular domain con-
tribute to the binding site. Three of these regions are on
the primary (þ) face of the subunit (loops A–C), and three
are on the complementary () face of the adjacent subunit
(loops D–F) (Fig. 1). Investigators have achieved a good
understanding of the residues involved in the ligand binding
in the homopentameric receptor, but it is still unclear which
residues are responsible in the heteromeric 5-HT3AB
receptor. This is particularly important because recent
studies suggest that the efficacy of antiemetic drugs depends
critically on the 5-HT3B subunit (18). The recently presented
architecture of the heteropentameric 5-HT3AB receptor (6)
offers three possibilities for the heteromeric binding site:
AþB, BþA, or BþB (A ¼ 5-HT3A subunit, B ¼
5-HT3B subunit). In this work, we used a range of tech-
niques (mutagenesis, modeling, radioligand binding, and
functional assays) to examine which, if any, of these binding
sites is correct. More specifically, we docked 5-HT and gra-
nisetron into the possible heteromeric binding sites to deter-
mine potential interactions with specific binding-site amino
acids, and, to test the resulting predictions, we substituteddoi: 10.1016/j.bpj.2009.12.4313
m5-HT3A MRLCIPQVLLALFLSMLTGPGEGSRRRATQARDTTQPALLRLSDHLLANYKKGVRPVRDW 60
m5-HT3B -MILLWSCLLVAVVGILG----------TATPQPGNSSLHRLTRQLLQQYHKEVRPVYNW 49
: : . **. .:.:* * : :. :.:* **: :** :*:* **** :*
m5-HT3A RKPTTVSIDVIMYAILNVDEKNQVLTTYIWYRQYWTDEFLQWTPEDFDNVTKLSIPTDSI 120
m5-HT3B AEATTVYLDLCVHAVLDVDVQNQKLKTSVWYREVWNDEFLSWNSSLFDEIQEISLPLSAL 109
:.*** :*: ::*:*:** :** *.* :***: *.****.*... **:: ::*:* .::
m5-HT3A WVPDILINEFVDVGKSPNIPYVYVHHRGEVQNYKPLQLVTACSLDIYNFPFDVQNCSLTF 180
m5-HT3B WAPDIIINEFVDVERSPDLPYVYVNSSGTIRNHKPIQVVSACSLQTYAFPFDIQNCSLTF 169
*.***:******* :**::*****: * ::*:**:*:*:****: * ****:*******
m5-HT3A TSWLHTIQDINITLWRSPEEVRSDKSIFINQGEWELLEVFPQFKEFSIDISNSYAEMKFY 240
m5-HT3B NSILHTVEDIDLGFLRNREDIENDKRAFMNDSEWQLLSVSSTYHIRQSSAG-DFAQIRFN 228
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FIGURE 1 (A) Location of the 5-HT3A subunit residues
(stick representation) that were mutated to the correspond-
ing 5-HT3B subunit residues. Two adjacent subunits
(principal and complementary) show the positions of the
six binding loops, A–F. Other residues of the putative
ligand-binding site are shown in line representation. (B)
ClustalW sequence alignment of the murine 5-HT3A
(accession number: Q6J1J7) and 5-HT3B subunits
(Q9JHJ5). 5-HT3A subunit residues that were mutated to
5-HT3B subunit residues in this study are highlighted as
white text on black background. The six binding loops
and the Cys loop are indicated by black lines above the
text. Numbering of residues and structural features are
taken from the AChBP protein crystal structure (13).
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binding in the 5-HT3A subunit to the corresponding 5-HT3B
subunit residues and vice versa, and expressed and tested
the resulting mutant receptors. The results suggest that the
5-HT3B subunit does not contribute to the binding site in
heteromeric 5-HT3AB receptors.MATERIALS AND METHODS
Modeling and docking studies
Modeling and docking studies were performed as described previously
(14,19). For the heteromeric 5-HT3AB open-state receptor model, the
protein sequences of the mouse 5-HT3A (accession number: Q6J1J7) and
5-HT3B receptor subunits (accession number: Q9JHJ5) were coaligned
with the sequence of AChBP from Lymnaea stagnalis (accession number:
P58154) using FUGUE (20). A three-dimensional homology model with
a 2A:3B subunit stochiometry and a B-B-A-B-A subunit arrangement
around the receptor rosette was generated using MODELER 6v2 (21) based
on the crystal structure of AChBP at 2.7 A˚ resolution (PDB ID: 1I9B). The
pentamer was generated by superimposing 5-HT3A or 5-HT3B subunits
onto each protomer of AChBP, and was then energy-minimized using the
force field implemented in MODELER 6v2. The best model was selected
after Ramachandran plot analysis of all the generated models. For the hetero-
meric 5-HT3AB closed-state receptor model, the protein sequences of the5-HT3A and 5-HT3B subunits were coaligned with the sequence of the
nACh receptor a1 subunit from Torpedo californica (accession number:
P02710). In a procedure similar to that described above, a three-dimensional
homology model was generated based on the cryo-electron microscopy
structure of the nACh receptor at 4 A˚ resolution (PDB ID: 2BG9).
The three-dimensional, protonated structure of 5-HT was extracted
from the Cambridge Structural Database (reference code: SERHOX) and
the counter anion was removed for the docking. The protonated form of
granisetron was constructed in Chem3D Ultra 7.0 (CambridgeSoft, Cam-
bridge, UK) based on the crystal structure of a related indazole carboxa-
mide (reference code: FIZXUH), and energy-minimized using the MM2
force field.
Docking of the protonated ligands into the heteromeric 5-HT3AB receptor
homology models was carried out using GOLD 3.0 (Cambridge Crystallo-
graphic Data Centre, Cambridge, UK). 5-HT was docked into the AþB,
BþA, and BþB interfaces of the open-state homology model (þ and 
denote the principal and complementary faces of the heteromeric binding
site, respectively), whereas granisetron was docked into the AþB,
BþA, and BþB interfaces of the closed-state homology model. The
following atoms were used as reference points for ligand docking: Cd2
atom of W183 and Cz atom of Y234 for Aþ face, Cd1 atom of W90 and
Cg atom of Y153 for A face, Cb atom of A219 and Cz atom of F222 for
Bþ face, and C32 atom of W79 and Cg atom of H142 for B face. The
amino acid residues were chosen based on the preferred binding-site models
of Reeves et al. (14) and Thompson et al. (19). Ten genetic algorithm runs
were performed on each docking exercise and the structures were analyzed
using the implemented GOLDScore fitness function.Biophysical Journal 98(8) 1494–1502
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Human embryonic kidney (HEK) 293 cells were maintained on 90 mm tissue
culture plates at 37C and 7% CO2 in a humidified atmosphere. They were
cultured in DMEM:F12 (Dulbecco’s modified Eagle’s medium/nutrient
mix F12 ; Gibco BRL, UK) with GlutaMAX I media containing 10% fetal
calf serum. For radioligand binding studies, cells in 90 mm dishes were
transfected using calcium phosphate precipitation at 80–90% confluency
and incubated for 3–4 days before use (22,23).
Harvested stage V–VI Xenopus oocytes were washed in four changes of
ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.5),
defolliculated in 1.5 mg mL1 collagenase Type 1A for ~2 h, washed again
in four changes of ND96, and stored in ND96 containing 2.5 mM sodium
pyruvate, 50 mM gentamycin, 0.7 mM theophylline. Mouse 5-HT3A and
5-HT3B subunit cDNA was cloned into pGEMHE for oocyte expression
(24). cRNA was in vitro transcribed from linearized (NheI) plasmid cDNA
template using the mMessage mMachine T7 Transcription kit (Ambion,
Austin, TX). Stage V and VI oocytes were injected with 20 ng cRNA, and
currents were recorded 1–4 days postinjection. A ratio of 1:3 (5-HT3A/
5-HT3B) was used for the expression of heteromeric 5-HT3 receptors.
Site-directed mutagenesis
Mutagenesis reactions were performed according to the method described by
Kunkel (25) using mouse 5-HT3A receptor subunit cDNA (accession
number: AY605711) or mouse 5-HT3B receptor subunit cDNA (accession
number: AF155045) in pcDNA3.1 (Invitrogen, Paisley, UK) as described
previously (26). Oligonucleotide primers were designed according to the
recommendations of Sambrook et al. (27) and some suggestions from the
Primer Generator (28). A silent restriction site was incorporated into each
primer to assist rapid identification.
Radioligand binding
Radioligand binding was performed as previously described, with minor
modifications (26). Briefly, transfected HEK 293 cell membranes were incu-
bated in 0.5 mL HEPES buffer containing the 5-HT3 receptor antagonist
[3H]granisetron (63.5 Ci/mmol; PerkinElmer, UK). Nonspecific binding
was determined using 1 mM quipazine. Incubations were terminated by
filtration, which limited our determination of Kd values to %~10 nM
because separation of bound from free ligand occurs too slowly to determine
Kd values greater than that (29). Data were analyzed by iterative curve-fitting
(Prism v3.0; GraphPad Software, San Diego, CA) according to the equation
B¼ (Bmax $ [L])/(Kd þ [L]), where B is bound radioligand, Bmax is maximum
binding at equilibrium, Kd is the equilibrium dissociation constant, and
[L] is the free concentration of radioligand. Values are presented as the
mean 5 SE. Statistical analysis was performed using analysis of variance
in conjunction with Dunnett’s posttest.
Immunoﬂuorescence
Immunofluorescence was achieved as described previously (30,31). Briefly,
transfected cells were fixed (4% paraformaldehyde) and incubated overnight
at 4C with a 5-HT3A or 5-HT3B specific antisera at 1:1000 in Tris-buffered
saline (0.1 M Tris, pH 7.4, 0.9% NaCl). Biotinylated anti-rabbit IgG (Vector
Laboratories, Burlingame, CA) and fluorescein isothiocyanate avidin D
(Vector Laboratories) were used to detect bound antibody as instructed by
the manufacturer. Coverslips were mounted in Vectashield HardSet mounting
medium (Vector Laboratories). Immunofluorescence was observed using an
UltraVIEW LCI confocal imaging system (Perkin Elmer, Boston, MA).
Electrophysiology
With the use of two electrode voltage clamps, Xenopus oocytes were
clamped at 60 mV using an OC-725 amplifier (Warner Instruments,
Hamden, CT), Digidata 1322A, and the Strathclyde ElectrophysiologyBiophysical Journal 98(8) 1494–1502Software Package (Department of Physiology and Pharmacology, Univer-
sity of Strathclyde, Glasgow, UK; http://www.strath.ac.uk/Departments/
PhysPharm/). Currents were filtered at a frequency of 1 kHz and sampled
at 350 Hz. Microelectrodes were fabricated from borosilicate glass
(GC120TF-10; Harvard Apparatus, Kent, UK) using a two-stage horizontal
pull (P-87; Sutter Instrument Co., Novato, CA) and filled with 3 M KCl.
Pipette resistances ranged from 0.5 to 1.5 MU. Oocytes were perfused
with saline at a rate of 15 mL min1. Drug application was achieved via
a simple gravity-fed system calibrated to run at the same rate. Extracellular
saline contained (mM) 96 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES, pH 7.4.
Analysis and curve-fitting was performed using Prism v3.0 (GraphPad Soft-
ware, San Diego, CA; http://www.graphpad.com). Concentration-response
data for each oocyte were normalized to the maximum current for that
oocyte. The mean and mean 5 SE for a series of oocytes were plotted
against agonist concentration and iteratively fitted to the following equation:
I ¼ Imin þ ðImax  IminÞ=ð1 þ 10logðEC50½LÞnH Þ; where Imin is the baseline
current, Imax is the peak current evoked by agonist, EC50 is the concentration
of agonist needed to evoke a half-maximum response, [L] is the concentra-
tion of agonist, and nH is the Hill coefficient. Statistical analysis was per-
formed using analysis of variance in conjunction with Dunnett’s posttest.RESULTS
Homology modeling and docking
Docking of 5-HT into the open-state model, and granisetron
into the closed-state model at the AþB, BþA, and
BþB interfaces revealed ligand orientations that were not
only quite distinct from each other, but also different from
orientations found at the AþA interface (14,19) (Fig. 2).
The latter was expected, since the 5-HT3B subunit shares
only ~45% sequence identity with the 5-HT3A subunit,
resulting in heteromeric subunit interfaces with unique archi-
tectures. The data show that in the AþB binding pocket,
the orientation of 5-HT is broadly similar to that proposed
for the AþA interface: the ammonium is located between
Trp-183 and Tyr-234, forming a hydrogen bond with the
backbone of Ser-182, and within cation-p interaction
distance of Trp-183. The hydroxyl group is in a pocket lined
by hydrophilic residues. In the AþB binding pocket, there
are hydrogen bonds with Glu-129, Tyr-234, and the back-
bone of Leu-184. The ammonium is no longer within
cation-p interaction distance of Trp-183. At the BþA
interface, 5-HT has a different orientation. It predominantly
interacts with residues from the complementary 5-HT3A
subunit, forming hydrogen bonds with the backbones of
Tyr-153 and Tyr-141, and the side chain of Gln-151, and
potentially undergoing a cation-p interaction with Tyr-143.
At the BþB interface, 5-HT forms hydrogen bonds with
Ser-217, Ser-218, and the backbone of Ser-171 (all Bþ).
Differences were also observed for granisetron, which at
the AþA interface is oriented such that the aromatic ring
of granisetron stacks face-to-face with Trp-183 and the azabi-
cyclic ring is close to Trp-90. In the AþB binding pocket,
granisetron undergoes an edge-to-face interaction with the
Trp-183 side chain and forms a hydrogen bond with
Tyr-234. Granisetron does not form any hydrogen bonds in
the BþA model, and appears relatively shallowly bound
between the A and B subunits. At the BþB interface,
FIGURE 2 Docking of 5-HT (yellow, left panels) and
granisetron (Grn, orange, right panels) into homomeric
5-HT3A (14,19) and heteromeric 5-HT3AB receptor
homology models. The 5-HT3A subunit is shown in violet,
and the 5-HT3B subunit is shown in teal. Residues within
4 A˚ of docked ligand are rendered in stick representation,
color-coded according to the corresponding subunits, and
numbered according to Fig. 1 B. The þ and  signs denote
the principal and complementary face of the binding site,
respectively. Proposed hydrogen bonds are shown as green
dotted lines. The orientation of the docking models is the
same as in Fig. 1 A.
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His-142 (B).
A closer analysis of the docking poses reveals that the
majority of the residues examined in this study are within
similar distances of the docked ligands in the heteromeric
models as compared to the homomeric model (Table 1).
This is to be expected because the structures used to generate
the models are the same for the A and B subunits; however,
since they are only homology models, they must be viewed
with some caution, unless there is experimental evidence to
verify specific interactions (e.g., the cation-p interaction with
Trp-183 (32)). Nevertheless, the similarities do support ouruse of the A subunit to probe potential interactions of B
subunit residues (see below).B-to-A mutant receptors
We created a series of A-like mutations in the 5-HT3B
subunit, where we substituted potential binding-site residues
in the 5-HT3B subunit into their equivalent locations in the
5-HT3A subunit. These were N170T and I172W (loop B),
F222Y (loop C), and H142Y (loop E). Loops A and D
have the same residues in 5-HT3A and 5-HT3B receptor
subunits, and loop F is currently poorly defined and thus itBiophysical Journal 98(8) 1494–1502
TABLE 1 Shortest distances between docked ligands and
speciﬁc residues in the A or B subunit
A: Shortest distances (A˚) between docked 5-HT and examined residues
Residue Loop AþA site AþB site BþA site BþB site
Y153/H142 E 2.4 2.9 3.0 3.5
T181/N170 B 4.0 5.6 8.4 4.2
W183/I172 B 3.2 2.8 2.5 3.0
F226/R215 C 4.1 4.2 8.4 3.0
I228/S217 C 3.8 5.8 6.7 2.8
Y234/F222 C 4.1 3.1 3.5 3.0
E236/Q224 C 3.4 7.0 10.3 3.8
B: Shortest distances (A˚) between docked granisetron and examined residues
Residue Loop AþA site AþB site BþA site BþB site
Y153/H142 E 2.0 3.1 3.3 2.5
T181/N170 B 3.0 4.1 3.5 2.9
W183/I172 B 2.9 3.1 2.8 3.5
F226/R215 C 3.9 6.2 6.3 3.5
I228/S217 C 3.2 8.6 7.2 3.6
Y234/F222 C 3.9 3.4 3.7 3.2
E236/Q224 C 4.0 5.8 7.0 4.0
FIGURE 3 HEK cells labeled with a 5-HT3B-selective antisera reveal
that both WT and mutant 5-HT3B receptor subunits reach the cell surface
when coexpressed with WT 5-HT3A receptor subunits. Scale bar: 20 mm.
TABLE 3 Functional effects of B-to-A substitutions at the
1498 Lochner and Lummisis not yet clear which residues face into the binding pocket.
Expression of these mutant receptors with wild-type (WT)
5-HT3A receptor subunits in HEK cells revealed no signifi-
cant changes in [3H]granisetron binding affinity compared to
WT heteromeric or homomeric receptors (Table 2), although
probing with a 5-HT3B selective antisera revealed that the B
subunits were expressed at the cell surface (Fig. 3). This was
as expected, since previous studies have shown that the
affinity of granisetron and many other 5-HT3 selective
ligands is similar in A-only and AB receptors.
Functional expression of WT heteromeric receptors
revealed an ~2-fold decrease in the Hill slope compared to
homomeric receptors, as previously reported (33), and we
also observed an ~2 fold increase in EC50 (Table 3).
However, expression of the mutant B subunits I172W,
F222Y, and H142Y with WT A receptor subunits revealed
EC50 and/or Hill slopes similar to those of homomeric recep-
tors. Because the B subunits did reach the cell surface
(Fig. 3), these data suggest that exchanging these residues
allows the B subunits to act as an A subunit and bind ligand.
However, we cannot exclude the possibility that homomeric
receptors are also expressed, and are responsible for the
A-like responses. Thus, to more specifically probe the poten-
tial role of these and other amino acid residues in the BTABLE 2 Effects of B-to-A substitutions on
[3H]granisetron-binding afﬁnities
Mutants Kd mean5 SE n
WT A 0.415 0.08 6
WT AB 0.555 0.12 4
AþBH142Y 0.445 0.09 4
AþBN170T 0.345 0.08 4
AþBI172W 0.655 0.12 4
AþBF222Y 0.715 0.20 4
Biophysical Journal 98(8) 1494–1502subunits, we used the A subunit, in which case we could
ensure that all of the data related specifically to changes in
these residues.
A-to-B mutant receptors
We created a series of B-like mutations in the 5-HT3A receptor
subunit (which has five AþA binding sites) to mimic the
effects of an adjacent 5-HT3B subunit. Loop B mutations
(T181N and W183I) and loop C mutations (F226R, I228S,
F234Y, and E236Q) are on the þ face, whereas the mutation
in loop E (Y153H) is on the  face (Fig. 1 A). In addi-
tion, we created seven double mutants (T181NW183I,
T181NF226R, Y153HW183I, Y153HI228S, W183IF226R,
F226RI228S, and F234YE236Q). Functional expression of
these mutant receptors revealed that exchanging even one of
the 5-HT3A subunit residues for its equivalent 5-HT3B
subunit residue has a considerably larger effect on the receptor
characteristics than has been observed in comparisons of a5-HT3 receptor
Mutants pEC50 mean5 SE EC50 (mM) nH mean5 SE n
WT A 6.125 0.02 0.75 2.225 0.23 13
WT AB 5.855 0.09* 1.42 1.125 0.17* 4
AþBH142Y 6.255 0.08y 0.57 1.895 0.35 4
AþBN170T 5.805 0.15 1.60 1.015 0.15* 6
AþBI172W 6.155 0.08y 0.70 2.315 0.23y 4
AþBF222Y 6.045 0.05y 0.92 2.305 0.32y 4
*Significantly different from WT A.
ySignificantly different from WT AB.
TABLE 5 Effects of A-to-B substitutions on
[3H]granisetron-binding afﬁnities
Single mutants Kd (nM) n Double mutants Kd (nM) n
WT A 0.415 0.08 6 WT A 0.415 0.08 6
Y153H NB* 3 Y153HW183I NB* 5
T181N 0.385 0.06 3 Y153HI228S NB* 5
W183I NB* 5 T181NW183I NB* 5
F226R 2.445 0.49* 5 T181NF226R NB* 5
I228S 2.535 0.60* 5 W183IF226R NB* 4
Y234F 0.725 0.18 3 F226RI228S 7.885 1.70* 4
E236Q 1.515 0.21* 3 Y234FE236Q 13.55 1.2*,y 4
*Significantly different from WT. NB ¼ no binding.
yKd > 10 nM may be inaccurate (see text for details).
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The difference in EC50 between a 5-HT3A and a 5-HT3AB
receptor is ~2-fold, but single mutations of 5-HT3A to
5-HT3B subunit binding-site residues resulted in EC50
increases of 4- to 15-fold, with functional double mutants
causing>100-fold increases (see Fig. 5). Most double mutants
and one single mutant (F226R) were nonfunctional (Table 4).
All of the A-to-B mutant receptors, except T181N, had a
lower [3H]granisetron binding affinity than the WT receptors
(Table 5).Bmax values varied considerably for different exper-
iments (as expected for transient transfections) and ranged
from ~200 to ~6000 fmol/mg protein. However, only
T181N (365 5 91 fmol/mg protein) mutant receptors had
significantly lower expression levels compared to WT recep-
tors (1516 5 378 fmol/mg protein), which suggests that
expression levels are not related to functional characteristics.
Mutations W183I, Y153H, T181NW183I, Y153HW183I,
Y153HI228S, T181NF226R, and W183IF226R caused
ablation of [3H]granisetron binding. Studies with a 5-HT3A
selective antisera revealed that all of the nonfunctional and
nonbinding receptors were expressed at the cell surface
(examples are shown in Fig. 4).DISCUSSION
The data presented here strongly suggest that the 5-HT3B
subunit does not contribute to the binding site in the mouse
heteromeric 5-HT3AB receptor. Because the binding site is
constituted from two adjacent subunits, residues from the
5-HT3B subunit could potentially contribute to an AþB,
BþA, or BþB binding site. The homology models of
5-HT3AB receptors indicate that both 5-HT and granisetron
could dock into all of these types of binding pockets, where
their interactions would be distinct from those that occur at
the AþA interface. The functional and radioligand binding
data, however, do not support a contribution from the B
subunit.
A major difference in the docked 5-HT at the AþB
compared to the AþA binding site is the lack of a
cation-p interaction at Trp-183. Such an interaction is foundTABLE 4 Functional effects of A-to-B substitutions at the
5-HT3 receptor
Mutants pEC50 mean5 SE EC50 (mM) nH mean5 SE n
WT A 6.125 0.02 0.75 2.225 0.23 13
Y153H 4.365 0.02* 43.4 2.945 0.33 7
T181N 5.305 0.01* 5.07 3.385 0.22* 8
W183I 4.755 0.02* 17.7 2.505 0.22 14
F226R NR* - - > 30
I228S 4.525 0.02* 30.4 2.875 0.39 9
Y234F 5.025 0.09* 9.6 1.825 0.42 6
E236Q 3.955 0.06* 111 1.545 0.34 7
T181NW183I 3.605 0.03* 254 1.545 0.18 8
F226RI228S NR* - - > 30
Y234FE236Q 3.865 0.01* 138 3.205 0.20 8
*Significantly different from WT. NR ¼ no response (up to 300 mM 5-HT).in neuronal nACh receptors between Trp-149 and nicotine,
but does not occur in the muscle nACh receptor, a loss
that results in such a major decrease in affinity for nicotine
that it can no longer act as an agonist (32). Thus, we would
anticipate that the loss of such an interaction in the 5-HT3AB
receptor would lead to a similar loss of ligand-binding
affinity, whereas the data show only a twofold change in
5-HT EC50, and no change in granisetron-binding affinity.
In addition, we might anticipate that removal of the hydroxyl
at Tyr-234, as in the Y234F substitution, would have a major
effect on receptor function, as the hydroxyl is predicted to
hydrogen bond with 5-HT, whereas such a substitution
causes only a relatively small increase in EC50.
In the BþA interface, 5-HT docks close to the A face,
but the cation-p interaction again is lost, which should lead
to a much greater loss of efficacy of 5-HT than is observed.
In addition, although substitution of Tyr-153 (with which
5-HT forms a hydrogen bond) with His should allow this
bond to be retained, it results in a large change in the EC50
and ablation of granisetron binding as described above.
Finally, at the BþB interface, there is again no cation-p
interaction with 5-HT, which we would anticipate would
lead to a large decrease in binding affinity. There is,
however, a predicted hydrogen bond between granisetron
and His-142 (equivalent to Tyr-153), but as we observed
no change in granisetron Kd when His-142 was substituted,
we propose that this ligand does not bind in a BþB pocket.
It is also striking that residues Thr-181, Phe-226, Ile-228,
and Glu-236, which are predicted to be much farther away
from the docked ligands in the B subunit-containing binding
sites, have such a significant effect on ligand binding and
receptor function. Thus, overall, the docking data show
that agonists and antagonists could potentially bind in
AþB, BþA, and BþB interfaces, but the experimental
data suggest that they do not.
This conclusion is supported by the functional and radio-
ligand binding data. We observed that incorporation of even
one B residue into the A-binding pocket has a much more
dramatic effect on the function of the receptor than is
observed in the WT 5-HT3AB receptor. [
3H]Granisetron-
binding data reveal a large difference in affinities or ablationBiophysical Journal 98(8) 1494–1502
FIGURE 4 Examples of HEK cells labeled with
5-HT3A-selective antisera, which reveals that both WT
and mutant 5-HT3A receptors subunits are expressed on
the cell surface. Scale bar: 20 mm.
1500 Lochner and Lummisof binding in heteromeric receptors with a B-like mutation in
their A subunits, but no change in affinity for B subunits with
A-like mutations.
The 5-HT3B subunit was the second 5-HT3 receptor
subunit to be identified, and it immediately raised great
interest because although it cannot form functional receptors
alone, when coexpressed with the 5-HT3A subunit, it alters
a number of biophysical properties. The most striking of these
is an increase in single-channel conductance of 1–2 orders of
magnitude, which is caused by specific residues in the M3–
M4 loop. Other effects include changes in the Hill slope,
desensitization kinetics, and the shape of the current-voltage
relationship, all of which could be explained by changes to
the transmembrane region (3,7–10,33). The pharmacological
characteristics of the 5-HT3AB receptors, however, are
almost identical to those of the homomeric 5-HT3A receptor.
Therefore, since the binding sites lie at subunit interfaces,
5-HT3AB receptors presumably contain at least one AþA
interface. It was therefore surprising that incompatible data
were obtained in a recent study. Barrera and co-workers (6)
used atomic force microscopy to image the heteromeric
receptor, which was expressed after distinct epitope tags
were engineered onto the two subunits. Images of receptors
that were doubly liganded by anti-epitope antibodies revealed
none where the antibodies were separated at an angle that
would indicate two 5-HT3A subunits were adjacent, although
they did observe this for tagged 5-HT3B subunits. Thus, they
concluded that the subunit arrangement around the receptor
rosette is B-B-A-B-A. At this time, we cannot explain the
discrepancy between their data and ours. It is possible that
there are distinct 5-HT3AB subunit arrangements in different
species (we used mouse and they used human). This is sup-
ported by the fact that the difference in EC50 is much greater
between A and AB receptors in humans (10- to 20-fold) than
in mice (1- to 2-fold) (33,34). However, opposing this argu-
ment is the fact that human 5-HT3AB receptors, like those inBiophysical Journal 98(8) 1494–1502the mouse, have a pharmacological profile similar to that of
human homomeric 5-HT3A receptors. It may be possible
that different cell types express different heteromeric recep-
tors, or that intracellular AB receptors (which would be
characterized by the atomic force microscopy study in addi-
tion to those expressed extracellularly) are of the wrong stoi-
chiometry. Considerably more work needs to be performed to
determine whether any of these possibilities are correct.
Our data also reveal some interesting features of the
5-HT3A receptor-binding site. The most surprising is that
substituting Trp-183 for Ile results in a functional receptor,
albeit with a ~20-fold increase in EC50 and no observable gra-
nisetron binding. As described above, Trp-183 is involved in
a cation-p interaction with 5-HT (32), and thus we speculate
that in the W183I mutant receptor there may be such an inter-
action with another aromatic binding-site residue. Molecular-
dynamics studies in the GABAC receptor, for example, have
shown that there is a potential for cation-p interactions with
two of the binding-site aromatics (35), and in the 5-HT-gated
MOD-1 receptor, the cation-p interaction can move from the
residue equivalent to Trp-183 (Tyr-180) to the residue equiv-
alent to Tyr-234 (Trp-226), because a Trp has the potential
for a stronger cation-p interaction than a Tyr (36).
Exchanging Phe-226 for Arg results in nonfunctional
receptors, whereas substitution of nearby Ile-228 for Ser
does not, although both mutations have a similar effect on
ligand binding (an ~5-fold increase in Kd). These data
support previous studies suggesting that different regions
of loop C have differential effects on ligand binding and
gating (15,19,37).CONCLUSIONS
In this work, we mutated binding-site residues in the
5-HT3A subunit to the corresponding 5-HT3B subunit resi-
dues and demonstrated that almost all of the resulting mutant
FIGURE 5 Example data for radioligand binding and functional studies of
WT and mutant receptors. (A) Kd values were estimated using the 5-HT3
receptor antagonist [3H]granisetron. The examples show binding curves
for single experiments, fitted with a one-site binding equation. Kd values
for a series of experiments were averaged for each mutant and are presented
in Tables 2 and 5. (B) Concentration response curves in 5-HT3 WT and
mutant receptors measured using two-electrode voltage clamp and fitted
with a four-parameter logistic equation. The calculated EC50 values are
shown in Tables 3 and 4. (C) Typical 5-HT responses from oocytes express-
ing WT and A-to-B mutant receptors.
Agonist and Antagonist Binding Site in 5-HT3AB Receptors 1501receptors had a significantly reduced antagonist-binding
affinity and increased 5-HT EC50. Conversely, we did
not observe any significant changes when we introduced
A-like mutations in the 5-HT3B subunit. Our docking
models show that it is possible for 5-HT and granisetron to
bind at AþB, BþA, and BþB interfaces; however,
the experimental data do not support the location of these
ligands in these heteromeric binding sites. We therefore
conclude that the 5-HT3B subunit does not contribute to
the binding site, and that 5-HT and granisetron bind to an
AþA interface in heteromeric 5-HT3AB receptors.
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